Why Kymera Therapeutics, Inc. (KYMR) stock moved
Kymera Therapeutics, Inc. (KYMR) shares fell 4.1% to $111.06 as of July 21, 2026, a moderate decline from the prior close of $115.77. BestStocks flagged the session as a major change for KYMR. No single company-specific catalyst was confirmed during the move window. Below, we break down what changed for KYMR, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
KYMR fell 4.1% to $111.06
KYMR fell 4.1% in its latest session, moving from $115.77 to $111.06.
What it means for Kymera Therapeutics, Inc. investors
For Kymera Therapeutics, Inc. investors, the recent signals add up to a bearish shift. On the constructive side: Kymera Therapeutics, Inc. (KYMR) moved +0.29% from $119.00 to $119.35 on 2026-07-10, reaching a new 30-day high; Kymera Therapeutics, Inc. (KYMR) moved +4.24% from $114.16 to $119.00 on 2026-07-09. Weighing against that: Negative session, down 4.1%; Kymera Therapeutics, Inc. (KYMR) moved −7.50% from $119.35 to $110.40 on 2026-07-13. Wall Street's consensus price target sits at $128.00, implying +15.3% upside from $111.06. Over the past 90 days analysts logged 0 upgrades and 1 downgrade. BestStocks rates the overall signal quality weak (0/100). With earnings roughly 20 days out, the next report is the most likely near-term test of the move.
KYMR price reaction
KYMR last traded at $111.06, down $4.71 (-4.07%) from the previous close of $115.77. The session traded on 0.7× average volume (below avg), so participation was unremarkable. Over the past month the stock has ranged between $98.25 and $119.35, and it currently sits about 61% of the way up that band.
Bullish and bearish analyst opinions on Kymera Therapeutics, Inc. (KYMR)
The consensus analyst price target on Kymera Therapeutics, Inc. (KYMR) is $128.00, 15.3% above the recent $111.06. Over the past 90 days analysts logged 0 upgrades, 6 maintains, and 1 downgrade. Here is how the bullish and bearish cases on KYMR line up.
The bullish case
- Wall Street's consensus price target of $128.00 implies +15.3% upside from $111.06.
- The Street's most bullish target is $155.00 (+39.6%).
- Kymera Therapeutics, Inc. (KYMR) moved +0.29% from $119.00 to $119.35 on 2026-07-10, reaching a new 30-day high.
- Positive price momentum.
The bearish case
- The most bearish analyst target is $97.00 (-12.7%).
- 1 analyst downgrade in the past 90 days, most recently RBC Capital to Sector Perform (2026-07-13).
- Negative session, down 4.1%.
- Kymera Therapeutics, Inc. (KYMR) moved −7.50% from $119.35 to $110.40 on 2026-07-13.
Weighing both sides, BestStocks' composite read of recent signals is bearish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Jul 21, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for KYMR
Frequently asked questions about KYMR
Why did Kymera Therapeutics, Inc. (KYMR) stock move?
KYMR fell 4.1% to $111.06. No single company-specific catalyst was confirmed during the move window, and it looks technical.
How much did KYMR stock fall?
KYMR lost 4.07% ($4.71) versus the prior close of $115.77, last trading at $111.06 on 0.7× average volume.
When is Kymera Therapeutics, Inc.'s next earnings date?
KYMR's next earnings report is estimated for 2026-08-10 — about 20 days away.
What is the analyst price target for KYMR?
The consensus analyst price target for KYMR is $128.00, about 15.3% above the current $111.06. Over the past 90 days, analysts recorded 0 upgrades, 6 maintains, and 1 downgrade.
How BestStocks tracks KYMR
This page is generated automatically by BestStocks' change-detection system after its price and volume cleared KYMR-specific materiality thresholds, triggering an evidence check. It draws on 8 tracked change events for KYMR, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of July 21, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.